Page last updated: 2024-11-04

pimobendan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pimobendan is a benzimidazole derivative that acts as a positive inotropic agent and vasodilator. It is used in veterinary medicine, particularly in dogs, to treat heart failure. It is synthesized through a multi-step process involving the reaction of benzimidazole with various reagents. Pimobendan enhances cardiac contractility by increasing calcium sensitivity and reducing afterload. Its vasodilatory effects contribute to reduced blood pressure and improved blood flow. Pimobendan is studied extensively due to its efficacy in improving heart function in dogs with heart failure. Its mechanisms of action, pharmacokinetics, and safety profile are actively researched to optimize its use in clinical practice.'

pimobendan: produces arterial & venous dilatation in dogs; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4823
CHEMBL ID24646
CHEBI ID32003
SCHEMBL ID27623
MeSH IDM0123429

Synonyms (124)

Synonym
AC-689
acardi
ud-cg-115bs
ud-cg-115
(+)-pimobendan
d-pimobendan
(+)-ud-cg 115bs
l-pimobendan
(+)-4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-3(2h)-pyridazinone
3(2h)-pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-, (+)-
(-)-ud-cg 115bs
3(2h)-pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-, (-)-
(-)-4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-3(2h)-pyridazinone
(-)-pimobendan
6-[2-(4-methoxyphenyl)-1h-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2h)-one
pimobendane
pimobendanum
CHEBI:32003 ,
pimobendan
pimobendan (jan/usan/inn)
D01133
acardi (tn)
74150-27-9
dl-pimobendan
6-(2-(4-methoxyphenyl)-4,5-dihydro-1h-benzimidazol-5-yl)-5-methyl-3(2h)-pyridazinone
ud-cg 115
racemic pinobendan
pimobendanum [inn-latin]
3(2h)-pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-
brn 4207330
vetmedin
pimobendan [inn-spanish]
pimobendane [inn-french]
ud-cg 115 bs
4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazole-5-yl)-5-methyl-3(2h)-pyridazinone
ud-cg115
udcg-115
racemic pimobendan
CHEMBL24646 ,
3-[2-(4-methoxyphenyl)-3h-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one
bdbm50282617
ksc-210-009
KUC109647N
4,5-dihydro-6-[2-(4-methoxyphenyl)-1h-benzimidazol-5-yl]-5-methyl-3(2h)-pyridazinone
unii-34ap3bbp9t
34ap3bbp9t ,
pimobendan [usan:inn:ban]
PIMOBENDAN - VETMEDIN
AKOS015967705
pimobendan, (+)-
118428-37-8
118428-38-9
pimobendan, (-)-
unii-9htu209z0n
613jxv89su ,
9htu209z0n ,
unii-613jxv89su
pimobendan (vetmedin)
BCP0726000255
FT-0630830
S1550
AKOS015851937
6-(2-(4-methoxyphenyl)-1h-benzo[d]imidazol-5-yl)-5-methyl-4,5-dihydropyridazin-3(2h)-one
pimobendan [usan]
118428-36-7
pimobendan [inn]
pimobendan [mart.]
pimobendan [jan]
pimobendan [ep impurity]
pimobendan component of fortekor plus
pimobendan [usp-rs]
pimobendan [usp monograph]
fortekor plus component pimobendan
(+/-)-4,5-dihydro-6-(2-(p-methoxyphenyl)-5-benzimidazolyl)-5-methyl-3(2h)-pyridazinone
pimobendan [who-dd]
pimobendan [green book]
pimobendan [mi]
3(2h)-pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-6-yl)-5-methyl-
pimobendan [ema epar veterinary]
3(2h)-pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-, (+/-)-
HY-B0204
smr002530068
MLS006010188
SCHEMBL27623
KS-1280
AB01274800-01
DTXSID8048280 ,
6-(2-(4-methoxyphenyl)-1h-benzo[d]imidazol-6-yl)-5-methyl-4,5-dihydropyridazin-3(2h)-one
AB01274800_02
J-517984
pimobendan, united states pharmacopeia (usp) reference standard
HMS3655I03
pimobendan for system suitability, european pharmacopoeia (ep) reference standard
pimobendan, >=98% (hplc)
mfcd00761648
NCGC00274063-05
4,5-dihydro-6-[2-(4-methoxyphenyl)-1h-benzimidazol-6-yl]-5-methyl-3(2h)-pyridazinone
SW219717-1
4,5-dihydro-6-[2-(4-methoxy-phenyl)-1h-benzimidazol-5-yl]-5-methyl-3 (2h)-pyridazinone
Q414351
DB11450
BCP02958
HMS3884C21
CCG-267853
pimobendan 100 microg/ml in acetonitrile
NCGC00274063-04
6-[2-(4-methoxyphenyl)-1h-1,3-benzodiazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one
EN300-27067685
P2779
pimobendan (mart.)
vetmedin-ca1
pimobendan (ep impurity)
vetmedinchew
pimobendanum (inn-latin)
dtxcid9028255
6-(2-(4-methoxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-4,5-dihydropyridazin-3(2h)-one
pimobendan (usp-rs)
pimobendane (inn-french)
solutitionkitspimobendan
pimobendan (ema epar veterinary)
pimobendan ep5
pimobendan,usp
pimobendan (usp monograph)
pimobendan (inn-spanish)

Research Excerpts

Overview

Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. It is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects.

ExcerptReferenceRelevance
"Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. "( The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
Bach, JP; Beyerbach, M; Klein, S; Nolte, I; Raue, JF; Rumstedt, K; Sehn, M; Treese, JS; Weiner, F, 2021
)
2.36
"Pimobendan is a PDE inhibitor recommended for medical treatment of certain stages of myxomatous mitral valve disease (MMVD) in dogs."( No impact of polymorphism in the phosphodiesterase 5A gene in Cavalier King Charles Spaniels on pimobendan-induced inhibition of platelet aggregation response.
Cremer, SE; Faisst, DN; Häggström, J; Knold, M; Ljungvall, I; Meurs, KM; Møller, JE; Olsen, LH; Reimann, MJ; Stern, JA,
)
1.07
"Pimobendan is an important therapy for dogs with myxomatous mitral valve disease (MMVD). "( Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
DeFrancesco, TC; McManamey, AK; Meurs, KM; Papich, MG,
)
1.9
"Pimobendan is a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects."( Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
Bode, EF; Dukes-McEwan, J; Hodgkiss-Geere, HM; Maddox, TW; Neves, J; Sarcinella, F, 2020
)
1.68
"Pimobendan is an inotropic drug with phosphodiesterase 3 inhibitory and calcium-sensitizing effects."( Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
Kawamoto, S; Miki, S; Morita, T; Nakamura, K; Osuga, T; Sasaoka, K; Takiguchi, M, 2020
)
1.57
"Pimobendan is a phosphodiesterase (PDE) inhibitor and calcium sensitizer with inotropic, lusitropic, and rasodilator properties used in the treatment of congestive heart failure. "( Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Beaufrère, H; Brandão, J; Guzman, DS; KuKanich, B; Paul-Murphy, J; Tully, TN, 2014
)
2.11
"Pimobendan is an inodilator used in dogs for the management of heart failure due to myxomatous valve disease or dilated cardiomyopathy. "( Cardiovascular effects of pimobendan in healthy mature horses.
Afonso, T; Barton, MH; Coleman, AE; Giguère, S; Rapoport, G, 2016
)
2.18
"Pimobendan is a benzimidazole-pyridazinone derivative, marketed as a racemic mixture for the management of canine heart failure. "( The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
Bell, ET; Chiu, S; Devi, JL; Whittem, T; Zahra, P, 2016
)
2.18
"Pimobendan is an inodilator used in the treatment of canine congestive heart failure (CHF). "( Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs.
Beijerink, NJ; Foster, DJ; McLachlan, AJ; Page, SW; Yata, M, 2016
)
2.09
"Pimobendan (PIMO) is a novel inodilator that has shown promising results in the treatment of advanced mitral valve disease (MVD), but little is known about its hemodynamic effects, especially regarding the mitral regurgitant volume in naturally occurring MVD."( Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
Beauchamp, G; Bélanger, MC; Difruscia, R; Ouellet, M,
)
1.98
"Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease."( Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
Atkinson, KJ; Durham, HE; Fine, DM; Gorelick, JJ; Thombs, LA,
)
1.93
"Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs. "( Current use of pimobendan in canine patients with heart disease.
Boswood, A, 2010
)
2.16
"Pimobendan (Vetmedin) is an effective treatment for canine chronic degenerative mitral valve disease and dilated cardiomyopathy. "( Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension.
Fox, S; Helms, SR; Mixon, W; Vail, J,
)
1.96
"Pimobendan is an inotropic and vasodilating drug with phosphodiesterase (PDE) III-inhibiting and calcium-sensitizing effects. "( Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases.
Kajimoto, K; Kasanuki, H; Kawana, M; Matsuda, N; Shiga, T; Wakaumi, M; Yajima, T, 2002
)
2.02
"Pimobendan is a drug with positive inotropic effects that additionally inhibits the production of proinflammatory cytokines."( The role of Ca++-sensitizers for the treatment of heart failure.
Boldt, J; Kirchner, J; Lehmann, A, 2003
)
1.04
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure. "( Use of pimobendan in the management of heart failure.
Fuentes, VL, 2004
)
2.22
"Pimobendan is a novel agent with properties that are highly desirable in the clinical management of congestive heart failure (CHF) secondary to both dilated cardiomyopathy (DCM) and chronic degenerative valvular disease in dogs. "( Pimobendan in heart failure therapy--a silver bullet?
Gordon, SG; Miller, MW; Saunders, AB,
)
3.02
"Pimobendan (PIMO) is an inodilator that may have some beneficial effects in canine degenerative mitral valve disease (MVD). "( Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study.
Chetboul, V; Concordet, D; Gouni, V; Lefebvre, HP; Nicolle, AP; Pouchelon, JL; Sampedrano, CC; Saponaro, V; Serres, F,
)
1.84
"Pimobendan is a novel cardiotonic vasodilator (inodilator) which derives its inotropic activity from a combination of phosphodiesterase III inhibition and sensitisation of myocardial contractile proteins to calcium. "( Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Brogden, RN; Fitton, A, 1994
)
3.17
"Pimobendan is a benzimidazole-pyridazinone derivative with calcium-sensitizing properties that increases myocardial contractile force without increasing intracellular calcium."( Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
Kubo, SH, 1997
)
1.41
"Pimobendan is a positive inotropic agent that dilates blood vessels and sensitizes the myocardium to calcium. "( [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].
Fujikane, T; Matsumoto, H; Sasaki, N; Shimizu, T; Takahashi, M; Takahashi, T; Takeda, A; Tsuji, T; Yamazaki, Y, 1997
)
2.12
"Pimobendan is a new class of inotropic drug that augments Ca2+ sensitivity and inhibits phosphodiesterase (PDE) activity in cardiomyocytes. "( The novel insulinotropic mechanism of pimobendan: direct enhancement of the exocytotic process of insulin secretory granules by increased Ca2+ sensitivity in beta-cells.
Fujimoto, S; Ishida, H; Kato, S; Mizuno, N; Mukai, E; Okamoto, Y; Seino, Y; Tsuji, K; Ueda, S, 1998
)
2.01
"Pimobendan is a new inotropic agent with vasodilator properties. "( Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
Chu, KM; Hu, OY; Shieh, SM, 1999
)
1.97
"Pimobendan is a so-called calcium sensitizer that exerts a positive inotropic action. "( Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs.
Fukutomi, T; Ichihara, K; Ogoshi, S; Satoh, K, 2000
)
2.14
"Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group. "( [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992
)
2.64
"Pimobendan (UD-CG 115) is a long-acting positive inotropic drug with arterio- and venodilator properties. "( Effects of pimobendan (UD-CG 115) on the contractile function of the normal and "postischemic" canine myocardium.
Balasim, H; Charlier, AA; Gurné, O; Hanet, C; Pouleur, H; Van Mechelen, H, 1988
)
2.11
"Pimobendan is a long-acting drug that effectively improves cardiac performance in patients with chronic congestive heart failure."( Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Brand, HJ; Hagemeijer, F; Roth, W, 1989
)
1.25

Effects

Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation. The molecular underlying mechanisms have not been fully elucidated. Pimob endan has almost the same mechanoenergetic effects as dobutamine but slightly greater contractile economy and coronary vasodilation.

ExcerptReferenceRelevance
"Pimobendan has a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting PDEIII. "( Effects of pimobendan for mitral valve regurgitation in dogs.
Hara, A; Kanno, N; Kano, R; Kawasaki, M; Kuse, H; Sasaki, Y, 2007
)
2.17
"Pimobendan has been proven to delay the onset of congestive heart failure (CHF) in dogs with mitral regurgitation (MR); however, molecular underlying mechanisms have not been fully elucidated. "( Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation.
Boonpala, P; Ji-Au, W; Kijtawornrat, A; Kumphune, S; Panyasing, Y; Saengklub, N; Srikam, S, 2023
)
3.8
"Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs. "( Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
Bach, JP; Iwanuk, N; Nolte, I; Pilgram, A; Raue, J; Rohn, K; Rumstedt, K; Sehn, M; Wall, L, 2019
)
2.36
"Pimobendan has been used in birds at the empirical dosage of 0.25 mg/kg q12h."( Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Beaufrère, H; Brandão, J; Guzman, DS; KuKanich, B; Paul-Murphy, J; Tully, TN, 2014
)
1.39
"Pimobendan has a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting PDEIII. "( Effects of pimobendan for mitral valve regurgitation in dogs.
Hara, A; Kanno, N; Kano, R; Kawasaki, M; Kuse, H; Sasaki, Y, 2007
)
2.17
"Pimobendan has been recently confirmed to improve both acute and chronic heart failure. "( Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis.
Iwasaki, A; Matsumori, A; Nishio, R; Okada, M; Ono, K; Sasayama, S; Shioi, T; Wang, W; Yamada, T, 1999
)
3.19
"Pimobendan has almost the same mechanoenergetic effects as dobutamine but slightly greater contractile economy and coronary vasodilation. "( Mechanoenergetic effects of pimobendan in canine left ventricles. Comparison with dobutamine.
Futaki, S; Goto, Y; Hata, K; Kawaguchi, O; Nishioka, T; Ohgoshi, Y; Saeki, A; Takasago, T; Taylor, TW; Yaku, H, 1992
)
2.02

Actions

Pimobendan (PIMO) can cause adverse effects, such as mitral valve degeneration, in dogs; however, it is unclear whether these effects occur in cats. The drug caused a 100% increase in contractility (+dP/dt mmHg/s) which remained elevated for approximately 4 h.

ExcerptReferenceRelevance
"Pimobendan (PIMO) can cause adverse effects, such as mitral valve degeneration, in dogs; however, it is unclear whether these effects occur in cats. "( Comparison of the effects of long-term pimobendan and benazepril administration in normal cats.
Machida, N; Miyagawa, Y; Takemura, N; Toda, N; Tominaga, Y, 2016
)
2.15
"Pimobendan caused a 100% increase in contractility (+dP/dt mmHg/s) which remained elevated for approximately 4 h."( Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism.
Iacono, G; Norton, K; Vezina, M,
)
0.85
"Pimobendan failed to increase cAMP levels in the skeletal muscle, though forskolin significantly increased it without any effect on twitch tension."( Effects of pimobendan, a new cardiotonic agent, on contractile responses in single skeletal muscle fibres of the frog.
Ito, S; Kai, T; Kitamura, N; Nakazato, Y; Ohta, T; Wakisaka, C,
)
1.24

Treatment

Pimobendan-treated dogs had a significant improvement in time to treatment failure. In pimob endan treated patients and volunteers an increase in forearm blood flow between 9% and 38% could be noticed. Pimob Endan was well tolerated compared with treatment with ramipril.

ExcerptReferenceRelevance
"Pimobendan treatment reduces heart size. "( Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018
)
2.12
"Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water."( Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Åblad, B; Belanger, MC; Borgarelli, M; Boswood, A; Bussadori, CM; Deinert, M; DiFruscia, R; Dukes-McEwan, J; Eggertsdottir, A; Eriksson, A; French, A; Gavaghan, B; Glaus, T; Häggström, J; Jöns, O; Kovačević, A; Kresken, JG; Kvart, C; Little, CJ; Lombard, CW; Louvet, A; Lynne O'Sullivan, M; O'Grady, M; Patteson, M; Rapp, M; Rønn-Landbo, M; Santilli, RA; Schneider, M; Smith, S; Swift, S; Tidholm, A; Wess, G; Willis, R,
)
1.05
"Pimobendan treatment enables the heart to work at smaller end-systolic and diastolic dimensions while maintaining adequate forward stroke volume."( Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström, J; Hansson, K; Höglund, K; Jöns, O; Kvart, C; Ljungvall, I; Lord, PF,
)
1.1
"Pimobendan-treated dogs had a significant improvement in time to treatment failure (pimobendan median, 130.5 days; placebo median, 14 days; P= .002; risk ratio = 0.35, P= .003, lower 5% confidence limit = 0.13, upper 95% confidence limit = 0.71). "( Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
Horne, R; Minors, SL; O'Grady, MR; O'Sullivan, ML,
)
1.98
"In pimobendan treated patients and volunteers an increase in forearm blood flow between 9% and 38% could be noticed."( [Effect of pimobendan on peripheral hemodynamics].
Kothe, A; Peters, P; Saborowski, F, 1989
)
1.18
"Treatment with pimobendan was well tolerated compared with treatment with ramipril. "( Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005
)
1
"Treatment with pimobendan also increased the mean Specific Activity Scale score from 4.39+/-0.12 at baseline to 4.68+/-0.15 at 52 weeks (p<0.05)."( Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
, 2002
)
1.04

Toxicity

Adverse effects will not differ between cats with OTO vs cats with nonobstructive cardiomyopathy. Adverse effects suspected to be related to pimobendan administration occurred in 12/260 cats.

ExcerptReferenceRelevance
" Other reasons for discontinuation and adverse events not leading to discontinuation were also comparable."( Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
Baiker, W; Baumann, G; Frick, MH; Haehl, M; Krayenbühl, HP; Nehmiz, G; Remme, WJ, 1994
)
0.57
" Adverse reactions developed in 26 of 241 (10."( Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
Kato, K, 1997
)
0.58
" Consequently, with respect to the pharmacological effects and the adverse events, the racemate is equivalent to the eutomer."( Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs.
Eckenfels, A; Güttner, J; Heinzel, G; Lehmann, H; Schneider, P; Trieb, G; von Nicolai, H, 1997
)
0.52
" The outcome measures studied were: adverse HF outcome, defined as failure to complete the trial as a direct consequence of HF; maximum furosemide dose (mg/kg/day) administered during the study period; and any requirement for additional visits to the clinic as a direct consequence of HF."( Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005
)
0.64
"In cats treated with pimobendan, incidence of adverse effects will not differ between cats with OTO vs cats with nonobstructive cardiomyopathy."( Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy.
DeFrancesco, TC; Keene, BW; Kussin, EZ; Tou, SP; Tropf, MA; Ward, JL, 2020
)
1.12
" Adverse effects suspected to be related to pimobendan administration occurred in 12/260 cats (4."( Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy.
DeFrancesco, TC; Keene, BW; Kussin, EZ; Tou, SP; Tropf, MA; Ward, JL, 2020
)
1.06
"Cardiovascular adverse effects in drug development are a major source of compound attrition."( An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
Gabrielsson, J; Jirstrand, M; Martel, E; Pairet, N; Scheuerer, S; Wallman, M, 2021
)
0.62

Pharmacokinetics

Pimobendan has a substantially longer elimination half-life and maximal drug plasma concentration in cats as compared to those previously reported in dogs. However, there is still a paucity of pharmacodynamic data refuting or supporting the use of pimob endan in a clinical cat population.

ExcerptReferenceRelevance
" The pharmacodynamic effect of pimobendan was evaluated by echocardiography."( Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu, KM; Hu, OY; Shieh, SM, 1995
)
0.82
" The present report focuses on the pharmacodynamic effect of pimobendan and a simultaneous pharmacokinetic-pharmacodynamic modeling."( Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
Chu, KM; Hu, OY; Shieh, SM, 1999
)
0.77
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Two cats were removed from final pharmacokinetic descriptive analysis due to delayed minimal absorption from gastrointestinal adverse effects."( Pharmacokinetics of oral pimobendan in healthy cats.
Borgarelli, M; Gehring, R; Hanzlicek, AS; Kukanich, B; Kukanich, KS; Margiocco, M; Olson, EE; Smee, N, 2012
)
0.68
"When administered a similar dose on a per weight basis, pimobendan has a substantially longer elimination half-life and maximal drug plasma concentration in cats as compared to those previously reported in dogs."( Pharmacokinetics of oral pimobendan in healthy cats.
Borgarelli, M; Gehring, R; Hanzlicek, AS; Kukanich, B; Kukanich, KS; Margiocco, M; Olson, EE; Smee, N, 2012
)
0.93
" Pharmacokinetic and pharmacodynamic studies have been published in humans, dogs, and cats, but there are no studies in avian species."( Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Beaufrère, H; Brandão, J; Guzman, DS; KuKanich, B; Paul-Murphy, J; Tully, TN, 2014
)
0.67
" Bioequivalence of the oral formulations was tested using CI90 for AUC(0-∞) and Cmax ."( The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
Bell, ET; Chiu, S; Devi, JL; Whittem, T; Zahra, P, 2016
)
0.74
" However, there is still a paucity of pharmacodynamic data refuting or supporting the use of pimobendan in a clinical cat population."( Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy.
Fousse, SL; Oldach, MS; Ontiveros, ES; Stern, JA; Ueda, Y; Visser, LC, 2021
)
1.12
" Plasma concentrations of pimobendan and O-demethylpimobendan (ODMP) were measured, and pharmacokinetic parameters were calculated for pimobendan by noncompartmental analysis."( Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).
Diao, SM; Gunther-Harrington, CT; Guzman, DS; Hawkins, MG; Knych, HK; Masri, AE; Ozawa, SM, 2022
)
1.34
" However, further studies evaluating multiple-dose administration as well as pharmacodynamic studies and clinical trials in rabbits with congestive heart failure are needed to determine accurate dose and frequency recommendations."( Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).
Diao, SM; Gunther-Harrington, CT; Guzman, DS; Hawkins, MG; Knych, HK; Masri, AE; Ozawa, SM, 2022
)
1.04
" Data was analyzed via a population pharmacokinetic approach and nonlinear mixed effects modeling (NLME)."( Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
DeFrancesco, TC; McManamey, AK; Meurs, KM; Papich, MG,
)
0.45
"The pharmacokinetic parameters were highly variable among this group of dogs with MMVD."( Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
DeFrancesco, TC; McManamey, AK; Meurs, KM; Papich, MG,
)
0.45

Compound-Compound Interactions

ExcerptReferenceRelevance
" We tried a beta-blocker combined with low-dose pimobendan in 2 patients who had refractory heart failure of NYHA functional class III or IV with idiopathic dilated cardiomyopathy (DCM) and chronic obstructive pulmonary disease (COPD)."( Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases.
Kajimoto, K; Kasanuki, H; Kawana, M; Matsuda, N; Shiga, T; Wakaumi, M; Yajima, T, 2002
)
0.83

Bioavailability

Pimobendan is well absorbed after oral administration and is metabolized in the liver to the O-demethyl metabolite, which is also active.

ExcerptReferenceRelevance
" Pimobendan is well absorbed and its duration of action is long."( Hemodynamic profile of the cardiotonic agent pimobendan.
Diederen, W; van Meel, JC, 1989
)
1.45
" Pimobendan is well absorbed after oral administration and is metabolized in the liver to the O-demethyl metabolite, which is also active."( Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes.
Hino, M; Igarashi, T; Ishii, I; Kitada, M; Kiuchi, M; Kuriya, Si; Nakamura, H; Ohmori, S; Senda, C, 2000
)
1.44
" Pharmacokinetics of the enantiomers of pimobendan and its oral bioavailability have not been described in dogs."( The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
Bell, ET; Chiu, S; Devi, JL; Whittem, T; Zahra, P, 2016
)
1.01
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72

Dosage Studied

Pimobendan has been used in birds at the empirical dosage of 0.5 mg. Administration of pimobendin at a standard dosage did not enhance or suppress furosemide-induced RAAS activation.

ExcerptRelevanceReference
") were administered in dosing regimens shown to produce equivalent and sustained increases in left ventricular (LV) + dP/dt."( Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.
Driscoll, EM; Frye, JW; Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC, 1989
)
0.52
"Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan."( Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu, KM; Hu, OY; Shieh, SM, 1995
)
0.8
"To evaluate the effect of administration of the labeled dosage of pimobendan to dogs with furosemide-induced activation of the renin-angiotensin-aldosterone system (RAAS)."( Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs.
Atkins, CE; DeFrancesco, TC; Keene, BW; Lantis, AC; Werre, SR, 2011
)
0.83
" Administration of pimobendan at a standard dosage did not enhance or suppress furosemide-induced RAAS activation."( Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs.
Atkins, CE; DeFrancesco, TC; Keene, BW; Lantis, AC; Werre, SR, 2011
)
0.92
" In 8 cats, blood samples were collected at 3 various time points on the first and third days of twice daily oral dosing of pimobendan for a total of 7 doses (0."( Pharmacokinetics of oral pimobendan in healthy cats.
Borgarelli, M; Gehring, R; Hanzlicek, AS; Kukanich, B; Kukanich, KS; Margiocco, M; Olson, EE; Smee, N, 2012
)
0.89
"To determine whether a high dosage of pimobendan, when administered concurrently with moderate-dosage furosemide to healthy dogs, would activate the renin-angiotensin-aldosterone system (RAAS) more than furosemide alone."( Effect of furosemide and high-dosage pimobendan administration on the renin-angiotensin-aldosterone system in dogs.
Ames, MK; Atkins, CE; Lantis, AC; Werre, SR, 2013
)
0.93
" Bioavailability of pimobendan after oral dosing was 70%."( The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
Bell, ET; Chiu, S; Devi, JL; Whittem, T; Zahra, P, 2016
)
1.06
"0 mg/kg benazepril dosed SID."( Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs.
Christinaz, C; Hornfeld, J; King, JN; Strehlau, G, 2018
)
0.78
" Angiotensin-converting enzyme inhibitor dosage and RAAS inhibition were greater in stage D, compared to stage C dogs."( Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020
)
0.56
" Poor furosemide dosage correlation to serum concentration may indicate variable and poor absorption, especially at higher dosages, advanced disease, or both."( Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020
)
0.56
" The findings of this prospective, acute-dosing study confirm previous findings in research animals and retrospective analyses and suggest that chronic dosing studies are safe and warranted."( Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy.
Fousse, SL; Oldach, MS; Ontiveros, ES; Stern, JA; Ueda, Y; Visser, LC, 2021
)
0.9
" An analysis of drug exposure-time and high-resolution response-time data of HR and mean arterial blood pressure was performed after acute oral dosing of ivabradine, sildenafil, dofetilide, and pimobendan in Han-Wistar rats."( An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
Gabrielsson, J; Jirstrand, M; Martel, E; Pairet, N; Scheuerer, S; Wallman, M, 2021
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
cardiotonic drugA drug that has a strengthening effect on the heart or that can increase cardiac output.
vasodilator agentA drug used to cause dilation of the blood vessels.
EC 3.1.4.* (phosphoric diester hydrolase) inhibitorAn EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a phosphoric diester hydrolase (EC 3.1.4.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridazinone
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency25.11890.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency20.93100.001310.157742.8575AID1259256
GVesicular stomatitis virusPotency19.49710.01238.964839.8107AID1645842
polyproteinZika virusPotency25.11890.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency19.49710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID48707Maximum increase in dP/dt from that of the control in the anesthetized rats at dose 10.0 mg/kg1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities.
AID220008Compound was evaluated for its inotropic activity by the inhibition of cAMP Phosphodiesterase enzyme1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID488211Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.
AID173453Effective dose required to produce an increase in dP/dt by 1500 mmHg/s from that of the control in the anesthetized rats.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID48720Maximum increase in dP/dt when administered intravenously in cats at 10 mg/kg dose.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID488212Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic ring assessed as inhibition of noradrenaline-induced contraction treated after noradrenaline challenge measured after 60 mins2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.
AID59419Maximum increase in dP/dt when administered intravenously in dogs at 1 mg/kg dose.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID58766Amount of time during which increase in administered orally in conscious dogs at 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID59118Effective dose required to produce an increase in dP/dt5 by 1500 mmHg/s in dogs1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID59424Maximum increase in dP/dt60 when administered orally in dogs at dose 1 mg/kg.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID62799Time after which maximum increase in contractility was observed when administered orally in conscious dogs at 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID47792Effective dose required to produce an increase in dP/dt5 by 1500 mmHg/s in cats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID47791Effective dose required to produce an increase in dP/dt by 1500 mmHg/s from that of the control in the anesthetized cats.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID185714Maximum increase in dP/dt when administered intravenously in rats at 3 mg/kg dose.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID185563Maximum increase in dP/dt from that of the control in the anesthetized rats at dose 3.0 mg/kg1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Nonsteroidal cardiotonics. 3. New 4,5-dihydro-6-(1H-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities.
AID173454Effective dose required to produce an increase in dP/dt5 by 1500 mmHg/s in rats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (314)

TimeframeStudies, This Drug (%)All Drugs %
pre-199061 (19.43)18.7374
1990's91 (28.98)18.2507
2000's56 (17.83)29.6817
2010's66 (21.02)24.3611
2020's40 (12.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.93 (24.57)
Research Supply Index6.03 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index159.32 (26.88)
Search Engine Supply Index3.91 (0.95)

This Compound (49.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials67 (19.25%)5.53%
Reviews35 (10.06%)6.00%
Case Studies24 (6.90%)4.05%
Observational0 (0.00%)0.25%
Other222 (63.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]